JOHNSON & JOHNSONJJ

JOHNSON & JOHNSON

154.6000GBPD
+1.7000+1.11%
Last update at May 30, 18:14 GMT
GBP
No trades
See on Supercharts

Key facts today


European regulators have reclassified JNJ-1900 from a medical device to a drug, aligning its status with the US and other markets, aiding Johnson & Johnson's regulatory efforts.
Analyze the impactAnalyze the impact
Volume
‪1.71 K‬
Previous close
152.9000 GBP
Open
153.8200 GBP
Day's range
153.2695 — 155.0800GBP
Employees (FY)
‪138.1 K‬
Change (1Y)
‪+6.2 K‬ +4.70%
Revenue / Employee (1Y)
‪514.07 K‬GBP
Net income / Employee (1Y)
‪81.41 K‬GBP

About Johnson & Johnson


CEO
Joaquin Duato
Website
Headquarters
New Brunswick
Founded
1887
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Performance
‪10%‬
‪21%‬
‪32%‬
‪43%‬
‪54%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪5.00 B‬‬
‪‪10.00 B‬‬
‪‪15.00 B‬‬
‪‪20.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪4.50 B‬‬
‪‪9.00 B‬‬
‪‪13.50 B‬‬
‪‪18.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪4.50 B‬‬
‪‪9.00 B‬‬
‪‪13.50 B‬‬
‪‪18.00 B‬‬
Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪11.00 B‬‬
‪‪22.00 B‬‬
‪‪33.00 B‬‬
‪‪44.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:Jul 16, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪0.60‬
‪1.20‬
‪1.80‬
‪2.40‬
Actual
Estimate

No news here

Looks like there's nothing to report right now

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US478160CS1
JOHNSON&JOHN 20/50
Yield to maturity
6.89%
Maturity date
Sep 1, 2050
US478160CT9
JOHNSON&JOHN 20/60
Yield to maturity
6.85%
Maturity date
Sep 1, 2060
US478160CR3
JOHNSON&JOHN 20/40
Yield to maturity
6.22%
Maturity date
Sep 1, 2040
US478160CM4
JOHNSON & JOHNSON 17/48
Yield to maturity
6.17%
Maturity date
Jan 15, 2048
US478160BV5
JOHNSON & JOHNSON 16/46
Yield to maturity
6.01%
Maturity date
Mar 1, 2046
JNJJ
JOHNSON & JOHNSON 17/47
Yield to maturity
5.96%
Maturity date
Mar 3, 2047
JNJB
JOHNSON & JOHNSON 13/43
Yield to maturity
5.48%
Maturity date
Dec 5, 2043
US478160CX0
JOHNSON&JOHN 24/54
Yield to maturity
5.45%
Maturity date
Jun 1, 2054
US478160CL6
JOHNSON & JOHNSON 17/38
Yield to maturity
5.42%
Maturity date
Jan 15, 2038
US478160CF9
JOHNSON & JOHNSON 17/37
Yield to maturity
5.22%
Maturity date
Mar 3, 2037
US478160BA1
JOHNSON & JOHNSON 11/41
Yield to maturity
5.20%
Maturity date
May 15, 2041

See all 0R34 bonds